SLC2A1 and prostate neuroendocrine neoplasm: Meziou et al. (2020) assumed that GLUT1 expression may be increased in neuroendocrine prostate carcinoma suggesting that [18F]FDG PET/CT might be an important imaging tool to examine neuroendocrine prostate carcinoma [43].